Drug manufacturer Tolmar recently said it plans refunds to 340B covered entities for overcharges on seven generic dermatologic products purchased [...] …
Category: Providers
Belgium drug maker UCB will add restrictions on 340B contract pharmacy use for hospitals starting Oct. 2, according to a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Arkansas Insurance Department (AID) has formally notified at least four drugmakers that they are in potential violation of a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) has awarded a $25.3 million, five-year contract to The Bizzell Group to audit [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Recent apparent changes to 340B drug pricing conditions by drug manufacturer Sanofi may eliminate 340B discounts for health centers using [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The congressional sponsor of legislation that would require hospitals and potentially other covered entities to publicly report their 340B revenue, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal district judge has allowed five major drugmakers to file friend-of-the-court briefs in a lawsuit over patient eligibility to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The boards of directors of health centers need to take on a bigger advocacy role in support of the 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A health center challenging the government’s 340B program patient definition in a federal district court recently asked a federal judge [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The nation’s largest hospital advocacy organization urged legislators to drop a provision from draft legislation that would exclude generic injectables [...] …